search

Active clinical trials for "Von Willebrand Disease, Type 3"

Results 1-3 of 3

Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A

Von Willebrand DiseaseType 31 more

Von Willebrand Disease (VWD) is the most common inherited bleeding disorder affecting up to 0.1% of the population, is usually characterized by mucocutaneous bleeding, HMB, surgical bleeding or other hemostatic challenges. Severe bleeding events require VWF concentrates administered solely through intravenous access. Emicizumab (Hemlibra) is a monoclonal bispecific antibody developed to bind activated FIX and FX and mimic FVIII cofactor functionality. Hemlibra is administered via subcutaneous injection rather than intravenous infusion. The hypothesis of this study is that Emicizumab is safe and efficacious for prophylaxis in severe VWD and concomitant VWD/hemophilia patients.

Recruiting26 enrollment criteria

Type 3 Von Willebrand International Registries Inhibitor Prospective Study

Type 3 Von Willebrand's Disease

International Registries and Prospective Study on Type 3 Von Willebrand's Disease (VWD3), aimed to assess number, types and risk factors for bleeding and the efficacy and safety of plasma-derived and/or recombinant Von Willebrand Factor (VWF) concentrates used to treat VWD patients.

Active6 enrollment criteria

Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant...

Von Willebrand Disease

The objectives of this study are to evaluate the immediate tolerability and safety of rVWF:rFVIII in subjects with Type 3 Von Willebrand Disease after administration of various dosages of VWF:RCo.

Completed32 enrollment criteria
1

Need Help? Contact our team!


We'll reach out to this number within 24 hrs